QUOTE AND NEWS
Market Intelligence Center  Nov 13  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on Bard (C.R.) Inc (BCR) could yield about 4.19% (23.54% annualized, for comparison purposes only) in 65 days. Pair a long position in the stock with the Jan. '15...
Market Intelligence Center  Nov 10  Comment 
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Bard (C.R.) Inc (BCR) that should provide a 3.79% return in just 68 days. Sell one Jan. '15 call at the $165.00 level for each 100 shares of...
Market Intelligence Center  Oct 22  Comment 
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Bard (C.R.) Inc (BCR). Look at the Jan. '15 $150.00 covered call for a net debit in the $144.52 area. This trade has a duration...
SeekingAlpha  Oct 16  Comment 
By Sure Dividend: In part 19 of the 54-part Dividend Aristocrats In Focus series, I analyze medical products creator C.R. Bard (NYSE:BCR). C.R. Bard was founded in 1907 and has grown to over $3 billion per year in sales. The company has a long...
StreetInsider.com  Oct 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/C.+R.+Bard+%28BCR%29+Reports+FDA+Approval+of+Lutonix+035+DCB+Catheter/9902442.html for the full story.
Market Intelligence Center  Oct 2  Comment 
For a hedged play on Bard (C.R.) Inc (BCR), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Nov. '14 $145.00 covered call for a net debit in the $139.13 area. That is also the break-even stock price for the covered...
Market Intelligence Center  Aug 28  Comment 
Bard (C.R.) Inc (BCR) presents a trading opportunity that offers a 3.37% return in just 51 days. A covered call on CR Bard at the $150.00 level expiring on Oct. '14 offers an assigned return rate of 3.37% or 24.12% annualized. This trade offers...
Market Intelligence Center  Aug 21  Comment 
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered-call trade on Bard (C.R.) Inc (BCR) that includes 2.75% downside protection. Sell one contract of the...




 
TOP CONTRIBUTORS

C.R. Bard (NYSE: BCR) manufactures medical devices such as stents and catheters. The company leads in market share in nearly all its markets.

Oncology was one of Bard's fastest growing therapeutic areas, with over 19% sales growth. Cancer is the second leading cause of death in developed countries and the third worldwide, and people spend billions of dollars annually on cancer research and treatment.

Business Overview

Business Segments

BCR breaks its operations into four segments: i) Vascular, ii) Urology, iii) Oncology, and iv) Surgical Specialties.

Urology Products (27% of 2009 Revenues)[1]

Bard’s leading urology product is the foley catheter, which Bard introduced in 1934. Other urology products include urine monitoring and collection systems, surgical slings (used to treat urinary incontinence), and other devices.

Vascular Products (28% of 2009 Revenues)[1]

Bard makes a wide range of products for the vascular market, including catheters, stents, accessories, and others.

Oncology Products (27% of 2009 Revenues)[1]

Bard’s oncology products cover a wide range of devices used in the treatment and management of various cancers, including specialty catheters, ultrasound devices, and feeding devices. [2]

Surgical Specialty Products (15% of 2009 Revenues)[1]

Bard’s surgical specialty products such as meshes and irrigation devices are primarily used for groin hernia repairs - Bard is the leader in this market segment.

Business Financials

BCR’s revenues are diversified across four operating divisions. BCR doesn’t have huge blockbuster products which contribute a significant amount of revenue, but rather a big diversified portfolio of products.

BCR has had steady growth over the past four years from 2006 to 2009. In 2009, total revenues were $2.53 billion, a modest increase from its previous year's revenues of $2.45 billion.[3] As a result of this increase in total revenues, BCR's 2009 net income rose to $460 million compared to $417 million for the previous year.[3]

Key Trends and Forces

Medicare coverage patterns impacts reimbursement

Health coverage is an important determining factor when patients and doctors choose among various treatment options. Medicare coverage is particularly significant in that it directly affects over forty million Americans, how much patients have to pay for Bard products, and how much Bard will receive in payments from Medicare. Currently, Medicare and other third party payors are emphasizing more cost-effective products and services, by limiting the reimbursement they will cover. Furthermore, even if a new medical or surgical device is cleared by the FDA, Bard faces limited demand for the device until Medicare and other payors approves it for reimbursement. Both of these factors can affect Bard's sales. Bard's products tend to be less controversial and significantly less expensive than some of its competitors, Medtronic's pace makers for instance, and therefore may be less affected by continuing governmental pressure to cut Medicare costs.

Increasing incidence of cancer drives double digit growth in Bard's oncology division

In the U.S. and other developed countries, cancer is responsible for around 25% of all deaths, second only to cardiovascular disease. The most common methods of treatment of Cancer are surgery, radiation therapy, and chemotherapy (drug therapy), which are often used in conjunction with one another to treat various aspects of cancer. Bard has a wide range of products which are used to treat and manage various aspects of cancer. If the incidence of cancer continues, this could continue to drive sales for the company's Oncology division.

Government regulation affects product launches

Bard and its competitors are all heavily affected by government regulation, especially by the FDA, which is responsible for regulating food, dietary supplements, drugs, medical devices, and other products in the United States. Without FDA approval, Bard cannot sell any of its medical products to the public. If any of Bard's products fail FDA approval, it can adversely affect the company's sales.

Competition

BCR faces formidable competition in all of its business divisions:

References

  1. 1.0 1.1 1.2 1.3 BCR 10-K 2009 Item 1 Pg. I-1
  2. BCR 2006 10k, I-3
  3. 3.0 3.1 BCR 10-K 2009 Item 6 Pg. II-2
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki